Aldehyde dehydrogenase 1A1—a new mediator of resistance to temozolomide in glioblastoma
Authors:
- Julian TeufelJTJulian Teufel
- Florian RingelFRFlorian Ringel
- Marcus BettstetterMBMarcus Bettstetter
- Ingrid HoepnerIHIngrid Hoepner
- Michael RasperMRMichael Rasper
- Jens GemptJGJens Gempt
- Julia KoeritzerJKJulia Koeritzer
- Friederike Schmidt-GrafFSFriederike Schmidt-Graf
- Bernhard MeyerBMBernhard Meyer
- Christoph P. BeierCBChristoph P. Beier
- Jürgen SchlegelJSJürgen Schlegel
Open Access
- 6 November 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 14 (12) , 1452-1464
Abstract
Implementation of chemotherapy with the drug temozolomide increased the overall survival of patients with glioblastoma multiforme (GBM; WHO grade IV), in particular when the O6-methylguanine DNA methyltransferase (MGMT) promoter is epigenetically silenced. Nevertheless, the prognosis remains poor, and relapse in GBM occurs regularly. This clinical behavior seems to be due to the existence of a therapy-resistant subpopulation of cells that induce tumor regrowth. The objective of this work was to analyze the role of aldehyde dehydrogenase (ALDH) 1A1 in mediating temozolomide resistance and its value as a predictor of clinical outcome in GBM patients. Nine GBM cell lines were treated with temozolomide alone or in combination with 4-diethylaminobenzaldehyde (DEAB), an inhibitor of ALDH1A1, or with ALDH1A1 short hairpin (sh)RNA. ALDH1A1 expression and MGMT status of 70 primary GBM patients were correlated with median survival. ALDH1A1 overexpression predicted temozolomide resistance in vitro. Sensitivity of ALDH1A1 positive/MGMT-positive cells to temozolomide could be restored by inhibition of ALDH1A1 by DEAB or by knockdown with shRNA, as indicated by increased cytotoxicity, reduced clonogenicity, and accumulation in the G2/M cell-cycle phase. The prognosis of patients with a high level of ALDH1A1 expression was poor compared with that of patients with low levels (P < .0001). ALDH1A1 is a new mediator for resistance of GBM to temozolomide and a reliable predictor of clinical outcome and may serve as a potential target to improve treatment of human GBM.Keywords
This publication has 47 references indexed in Scilit:
- Aberrant Expression of Retinoic Acid Signaling Molecules Influences Patient Survival in Astrocytic GliomasThe American Journal of Pathology, 2011
- Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 InhibitionJournal of Biological Chemistry, 2010
- Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheresCancer Letters, 2010
- ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcomeLaboratory Investigation, 2009
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Multiple and Additive Functions of ALDH3A1 and ALDH1A1Journal of Biological Chemistry, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cellsProceedings of the National Academy of Sciences, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005